For this reason, a last observation carried forward (LOCF) week 48 Framingham score was calculated post hoc. For patients without week 48 data, their LOCF values for SBP, TC, HDL-c and smoking

status were used for week 48 and their age at week 48 was calculated. Screening SBP, TC and HDL-c values were substituted for missing baseline values. The study was carried out in accordance with good clinical practice and the ethical principles of the Declaration of Helsinki. Written informed consent was obtained from all subjects. The trial protocol, amendments, informed consent and subject information form were reviewed and approved by the local Institutional Review Board or Independent Ethics Committee. In order to evaluate the differences in lipid levels after 48 weeks of treatment, the mean change

from baseline in TC, HDL-c, LDL-c, TC:HDL-c selleck products ratio and TG values was compared between the treatment groups. An intent-to-treat (ITT) analysis was carried out and an LOCF approach was used to replace missing values at week 48. Analyses of covariance (ancovas) were performed comparing the combined NVP groups vs. the AZT/r group with respect to change from baseline in TC, HDL-c, LDL-c, TC:HDL-c ratio, ApoA1, ApoB, TG and Framingham score. The respective baseline value was used as a PD0332991 mouse covariate and the stratification categories used in the randomization (screening viral load > or ≤100 000 copies/mL and screening CD4 count ≥ or <50 cells/μL) as factors in the model. All analyses were two-sided with an alpha level of 0.05. No adjustment for multiple testing was made as all analyses were on secondary outcomes. All statistical analyses were performed using sas version 8.2 (SAS Institute, Cary, NC, USA). At baseline, the combined Venetoclax in vitro NVP and the ATZ/r treatment groups had comparable mean lipid values (Table 1). Figure 1 shows mean lipid parameters over time. From week 4 onwards, NVP-treated patients had a greater mean increase from baseline in TC compared with ATZ/r-treated patients. The mean increase in TC from baseline to week 48 was significantly higher in the combined NVP group compared with the

ATZ/r group (P=0.038). In contrast, the mean increase from baseline in TG at week 48 was significantly greater in the ATZ/r group than in the combined NVP group (P=0.0001) (Table 1). The mean increase in HDL-c levels from baseline to week 48 was significantly different between the combined NVP and the ATZ/r groups, with the NVP group achieving greater mean increases compared with the ATZ/r group (9.66 vs. 3.89 mg/dL, respectively; P<0.0001). A greater mean increase in LDL-c levels from baseline to week 48 was also observed in the combined NVP group compared with the ATZ/r group (14.98 vs. 10.43 mg/dL, respectively; P=0.011). Significant differences were found between the combined NVP group and the ATZ/r group with regard to the effects on the TC:HDL-c ratio.